...
首页> 外文期刊>Journal of Animal Science >Effect of a novel animal milk oligosaccharide biosimilar on macronutrient digestibility and gastrointestinal tolerance, fecal metabolites, and fecal microbiota of healthy adult cats
【24h】

Effect of a novel animal milk oligosaccharide biosimilar on macronutrient digestibility and gastrointestinal tolerance, fecal metabolites, and fecal microbiota of healthy adult cats

机译:一种新型动物牛奶寡糖生物素对健康成人猫的常规饲料消化率和胃肠道耐受性,粪便代谢物和粪便微生物的影响

获取原文
获取原文并翻译 | 示例
           

摘要

GNU100 is a novel animal milk oligosaccharide (AMO) biosimilar. In a recent in vitro fermentation study, GNU100 was shown to be fermentable by feline gastrointestinal microbiota and lead to increased short-chain fatty acid production. Our objectives herein were to evaluate the palatability, safety, and gastrointestinal tolerance of GNU100 in healthy adult cats. Exploratory end-points were measured to assess utility. In study 1, 20 adult cats were used to test the palatability of diets containing 0% or 1% GNU100. In study 2, 32 (mean age = 1.9 yr; mean body weight = 4.6 kg) male (n = 12) and female (n = 20) adult cats were used in a completely randomized design. After a 2-wk baseline, cats were assigned to one of the following treatment groups and fed for 26 wk: control (CT, no GNU100), low dose (LD, 0.5% GNU100), medium dose (MD, 1.0% GNU100), and high dose (HD, 1.5% GNU100). On weeks 2, 4, and 26, fresh fecal samples were collected for the measurement of stool quality and immune and inflammatory markers and on weeks 2 and 4 for microbiota and metabolites. On week 4, total feces were collected to measure apparent total tract macronutrient digestibility. On weeks 2, 4, and 26, blood samples were collected for serum chemistry, hematology, and inflammatory marker measurement. The palatability test showed that 1% GNU100 was strongly preferred (P < 0.05), with GNU100 having a 17.6:1 consumption ratio compared with control. In the long-term study, all cats remained healthy, without any signs of gastrointestinal intolerance or illness. All diets were well accepted, resulting in similar (P > 0.05) food intake, fecal characteristics, immunoglobulin A, and calprotectin, and dry matter, organic matter, fat, and crude protein digestibilities. Fecal butyrate was greater (P = 0.02) in cats fed HD than cats fed LD or MD. Fecal indole was lower (P = 0.02) in cats fed HD than cats fed LD. Cats fed CT had a higher (P = 0.003) relative abundance of Actinobacteria than cats fed LD. The relative abundance of Peptococcus was impacted by diet and time. At 4 wk, Campylobacter was lower in fecal samples of cats fed HD. Overall, the data suggest that dietary GNU100 supplementation was highly palatable, well tolerated, did not cause detrimental effects on fecal quality or nutrient digestibility, increased fecal butyrate concentrations, and reduced fecal indole concentrations, supporting the safety of GNU100 for inclusion in feline diets and suggesting potential benefits on gastrointestinal health of cats.
机译:GNU100是一种新型的动物乳低聚糖(AMO)生物仿制品。最近的一项体外发酵研究表明,GNU100可被猫胃肠道微生物群发酵,并导致短链脂肪酸产量增加。我们的目的是评估GNU100在健康成年猫中的适口性、安全性和胃肠道耐受性。测量探索终点以评估效用。在研究1中,20只成年猫被用来测试含有0%或1%GNU100的饮食的适口性。在研究2中,32只(平均年龄=1.9岁;平均体重=4.6公斤)雄性(n=12)和雌性(n=20)成年猫被用于完全随机设计。基线检查2周后,将猫分配到以下治疗组之一,并喂食26周:对照组(CT,无GNU100)、低剂量组(LD,0.5%GNU100)、中剂量组(MD,1.0%GNU100)和高剂量组(HD,1.5%GNU100)。在第2周、第4周和第26周,收集新鲜粪便样本以测量粪便质量、免疫和炎症标记物,并在第2周和第4周收集微生物群和代谢物。第4周,收集总粪便,以测量表观总肠道大量营养素消化率。在第2周、第4周和第26周,采集血样进行血清化学、血液学和炎症标志物测量。适口性测试表明,1%的GNU100是首选(P<0.05),与对照组相比,GNU100的食用率为17.6:1。在长期研究中,所有猫都保持健康,没有任何胃肠道不耐受或疾病的迹象。所有饮食都被广泛接受,导致食物摄入量、粪便特征、免疫球蛋白A和钙卫蛋白、干物质、有机物质、脂肪和粗蛋白质消化率相似(P>0.05)。喂食HD的猫比喂食LD或MD的猫的粪便丁酸更高(P=0.02)。喂食HD的猫的粪便吲哚比喂食LD的猫的粪便吲哚更低(P=0.02)。喂食CT的猫的放线菌相对丰度高于喂食LD的猫(P=0.003)。消化球菌的相对丰度受饮食和时间的影响。4周时,喂食HD的猫的粪便样本中弯曲杆菌含量较低。总的来说,数据表明,饮食中补充GNU100非常美味,耐受性良好,不会对粪便质量或营养物消化率造成有害影响,增加粪便丁酸盐浓度,降低粪便吲哚浓度,支持GNU100在猫粮中的安全性,并表明对猫的胃肠健康有潜在益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号